These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 26966281)
41. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598 [TBL] [Abstract][Full Text] [Related]
42. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Rosenson RS Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615 [TBL] [Abstract][Full Text] [Related]
43. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Schachter M Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091 [TBL] [Abstract][Full Text] [Related]
44. [Can cardiovascular events be prevented by raising HDL cholesterol?]. Langslet G; Reikvam A Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459 [TBL] [Abstract][Full Text] [Related]
45. The treatment of dyslipidemia--what's left in the pipeline? Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209 [TBL] [Abstract][Full Text] [Related]
46. Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Quispe R; Al-Hijji M; Swiger KJ; Martin SS; Elshazly MB; Blaha MJ; Joshi PH; Blumenthal RS; Sniderman AD; Toth PP; Jones SR J Clin Lipidol; 2015; 9(4):511-8.e1-5. PubMed ID: 26228668 [TBL] [Abstract][Full Text] [Related]
47. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249 [TBL] [Abstract][Full Text] [Related]
48. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902 [TBL] [Abstract][Full Text] [Related]
49. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Windler E; Schöffauer M; Zyriax BC Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448 [TBL] [Abstract][Full Text] [Related]
50. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274 [TBL] [Abstract][Full Text] [Related]
51. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307 [TBL] [Abstract][Full Text] [Related]
53. High density lipoprotein - should we raise it? Landmesser U Curr Vasc Pharmacol; 2012 Nov; 10(6):718-9. PubMed ID: 23259564 [TBL] [Abstract][Full Text] [Related]
54. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Jafri H; Alsheikh-Ali AA; Karas RH Ann Intern Med; 2010 Dec; 153(12):800-8. PubMed ID: 21173414 [TBL] [Abstract][Full Text] [Related]
55. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. Badimón JJ; Santos-Gallego CG; Badimón L Rev Esp Cardiol; 2010 Jun; 63 Suppl 2():20-35. PubMed ID: 20540898 [TBL] [Abstract][Full Text] [Related]
56. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Shapiro MD; Fazio S Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970 [TBL] [Abstract][Full Text] [Related]